| Year |
Citation |
Score |
| 2023 |
Sisler DJ, Hinz TK, Le AT, Kleczko EK, Nemenoff RA, Heasley LE. Evaluation of KRAS inhibitor responses in novel murine KRAS lung cancer cell line models. Frontiers in Oncology. 13: 1094123. PMID 36845684 DOI: 10.3389/fonc.2023.1094123 |
0.665 |
|
| 2023 |
Kleczko EK, Hinz TK, Nguyen TT, Gurule NJ, Navarro A, Le AT, Johnson AM, Kwak J, Polhac DI, Clambey ET, Weiser-Evans M, Merrick DT, Yang MC, Patil T, Schenk EL, et al. Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity. Npj Precision Oncology. 7: 15. PMID 36739466 DOI: 10.1038/s41698-023-00355-2 |
0.649 |
|
| 2023 |
Kleczko EK, Poczobutt JM, Navarro AC, Laskowski J, Johnson AM, Korpela SP, Gurule NJ, Heasley LE, Hopp K, Weiser-Evans MCM, Gottlin EB, Bushey RT, Campa MJ, Patz EF, Thurman JM, et al. Upregulation of complement proteins in lung cancer cells mediates tumor progression. Frontiers in Oncology. 12: 1045690. PMID 36686777 DOI: 10.3389/fonc.2022.1045690 |
0.628 |
|
| 2023 |
Kleczko EK, Le AT, Hinz TK, Nguyen TT, Navarro A, Hu CJ, Selman AM, Clambey ET, Merrick DT, Lu S, Weiser-Evans M, Nemenoff RA, Heasley LE. Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response. Cancer Letters. 216062. PMID 36657561 DOI: 10.1016/j.canlet.2023.216062 |
0.721 |
|
| 2021 |
Gadwa J, Bickett TE, Darragh LB, Knitz MW, Bhatia S, Piper M, Van Court B, Bhuvane S, Nguyen D, Nangia V, Kleczko EK, Nemenoff RA, Karam SD. Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer. Journal For Immunotherapy of Cancer. 9. PMID 33789881 DOI: 10.1136/jitc-2021-002585 |
0.36 |
|
| 2020 |
Johnson AM, Kleczko EK, Nemenoff RA. Eicosanoids in Cancer: New Roles in Immunoregulation. Frontiers in Pharmacology. 11: 595498. PMID 33364964 DOI: 10.3389/fphar.2020.595498 |
0.42 |
|
| 2020 |
Neuwelt AJ, Kimball AK, Johnson AM, Arnold BW, Bullock BL, Kaspar RE, Kleczko EK, Kwak JW, Wu MH, Heasley LE, Doebele RC, Li HY, Nemenoff RA, Clambey ET. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. Journal For Immunotherapy of Cancer. 8. PMID 32312906 DOI: 10.1136/Jitc-2019-000441 |
0.577 |
|
| 2019 |
Hinz TK, Kleczko EK, Singleton KR, Calhoun J, Marek LA, Kim J, Tan AC, Heasley LE. Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. Molecular Pharmacology. PMID 31554698 DOI: 10.1124/Mol.119.117804 |
0.779 |
|
| 2019 |
Kleczko EK, Kwak JW, Schenk EL, Nemenoff RA. Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. Frontiers in Immunology. 10: 954. PMID 31134065 DOI: 10.3389/Fimmu.2019.00954 |
0.486 |
|
| 2019 |
Bullock BL, Kimball AK, Poczobutt JM, Neuwelt AJ, Li HY, Johnson AM, Kwak JW, Kleczko EK, Kaspar RE, Wagner EK, Hopp K, Schenk EL, Weiser-Evans MC, Clambey ET, Nemenoff RA. Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC. Life Science Alliance. 2. PMID 31133614 DOI: 10.26508/lsa.201900328 |
0.348 |
|
| 2019 |
Sippel TR, Johnson AM, Li HY, Hanson D, Nguyen TT, Bullock BL, Poczobutt JM, Kwak JW, Kleczko EK, Weiser-Evans MC, Nemenoff RA. Activation of PPARγ in Myeloid Cells Promotes Progression of Epithelial Lung Tumors Through TGF-β1. Molecular Cancer Research : McR. PMID 31088909 DOI: 10.1158/1541-7786.Mcr-19-0236 |
0.506 |
|
| 2018 |
Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K. CD8 T cells modulate autosomal dominant polycystic kidney disease progression. Kidney International. PMID 30249452 DOI: 10.1016/J.Kint.2018.06.025 |
0.328 |
|
| 2018 |
Kleczko EK, Heasley LE. Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Molecular Cancer. 17: 60. PMID 29458371 DOI: 10.1186/S12943-018-0816-Y |
0.721 |
|
| 2015 |
Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. Cancer Research. 75: 4398-406. PMID 26359452 DOI: 10.1158/0008-5472.Can-15-0509 |
0.779 |
|
| 2015 |
Göke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Mässenhausen A, Lankat-Buttgereit B, Göke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, et al. FGFR1 expression levels predict BGJ398-sensitivity of FGFR1-dependent head and neck squamous cell cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26015511 DOI: 10.1158/1078-0432.Ccr-14-3357 |
0.687 |
|
| 2015 |
Kleczko EK, Kim J, Keysar SB, Heasley LR, Eagles JR, Simon M, Marshall ME, Singleton KR, Jimeno A, Tan AC, Heasley LE. An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. Plos One. 10: e0123600. PMID 25946135 DOI: 10.1371/Journal.Pone.0123600 |
0.77 |
|
| 2014 |
Marek LA, Hinz TK, von Mässenhausen A, Olszewski KA, Kleczko EK, Boehm D, Weiser-Evans MC, Nemenoff RA, Hoffmann H, Warth A, Gozgit JM, Perner S, Heasley LE. Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Molecular Cancer Research : McR. 12: 1460-9. PMID 24966347 DOI: 10.1158/1541-7786.Mcr-14-0038 |
0.746 |
|
| 2013 |
Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2: e39. PMID 23552882 DOI: 10.1038/oncsis.2013.4 |
0.706 |
|
| 2013 |
Kleczko EK, Heasley LR, Marshall ME, Singleton KR, Heasley LE. Abstract 3387: Tyrosine kinase inhibitors induce TGF-β2 expression in head and neck squamous cell carcinoma cell lines as a mechanism of acquired resistance. Cancer Research. 73: 3387-3387. DOI: 10.1158/1538-7445.Am2013-3387 |
0.691 |
|
| 2012 |
Kleczko EK, Heasley L, Heasley LE. Abstract B29: TGF- 2 induction in head and neck squamous cell carcinoma cell lines upon treatment with tyrosine kinase inhibitors as a mechanism of acquired resistance Clinical Cancer Research. 18: B29-B29. DOI: 10.1158/1078-0432.Mechres-B29 |
0.76 |
|
| Show low-probability matches. |